Sickle Cell Disease (SCD) Clinical Trials and Treatments

Sickle cell disease is an autosomal recessive hemoglobinopathy caused by a single nucleotide substitution in the beta-globin gene (GAG→GTG codon 6), resulting in glutamic acid→valine substitution that promotes hemoglobin polymerization under conditions of low oxygen tension. Under deoxygenation, hemoglobin S polymerizes into long fibers that distort red blood cells into rigid, sickle shapes. These sickled cells cause hemolysis (destroying red blood cells), leading to severe anemia and jaundice, and cause vaso-occlusion (blockade of blood vessels), leading to severe pain, organ infarction, and progressive organ damage.

The most common symptoms of Sickle Cell Disease include Severe pain crises (vaso-occlusive pain episodes), Chronic hemolytic anemia and jaundice, Acute chest syndrome with chest pain and breathing difficulty, Organ damage including strokes and kidney disease, Priapism (painful sustained erection) in males, among others. About 100,000 Americans with SCD; about 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Sickle Cell Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Sickle cell disease treatment is advancing dramatically with gene therapy successes and newer disease-modifying approaches including fetal hemoglobin induction therapies. Base editing and other novel genetic approaches are entering human testing.

Yes. As of October 14, 2026, 6 FDA-approved medicines have a current label that names Sickle Cell Disease: Adakveo (crizanlizumab), first approved in 2019; Casgevy (exagamglogene autotemcel), first approved in 2023; Droxia (hydroxyurea), first approved in 1998; Endari (l-glutamine), first approved in 2017; Lyfgenia (lovotibeglogene autotemcel), first approved in 2023; and Ferriprox (deferiprone). Corticosteroids and immune globulins count once each. The FDA is due to decide on Mitapivat by November 1, 2026; the FDA calendar page carries the outcome the day it lands.

Sickle Cell Disease is caused by variants in the HBB gene. HbSS is homozygous for the sickle HBB variant; HbSC and HbS-beta-thalassemia combine it with another HBB variant.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. About 100,000 Americans with SCD; about 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Sickle Cell Disease looks at the HBB gene. HbSS is homozygous for the sickle HBB variant; HbSC and HbS-beta-thalassemia combine it with another HBB variant.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Sickle Cell Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Sickle Cell Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.